RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis
US8940887B2 · kind B2 · utility
32Cited by
1References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 29, 2013 |
| Grant date | Jan 27, 2015 |
| Priority date | — |
| Expiry date | May 29, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/31
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
RNA interference is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.